MiSight® Clinical Study (1 of 2) (IMAGE)

McDougall Communications

MiSight® Clinical Study (1 of 2)

Caption

New four-year study data shows the significant impact of a pioneering CooperVision® MiSight® contact lens management approach to slowing the progression of myopia (nearsightedness) in children, including those whose treatment begins later. Axial length growth of 0.07mm in the MiSight® group and 0.06mm in the previous control group, compared to 0.10mm seen in the MiSight® group in year three, represents further myopia slowing as the children age.

Credit

CooperVision

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.